VWA5A Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
VWA5A Peptide Applications :
Blocking Background :
VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A. Alternative Name :
von Willebrand factor A domain-containing protein 5A; Breast cancer suppressor candidate 1; BCSC-1; Loss of heterozygosity 11 chromosomal region 2 gene A protein; BCSC1; LOH11CR2A Swiss-Prot :
O00534 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide VWA5A. (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS5627 VWA5A pAb.
VWA5A Peptide Applications :
Blocking Background :
VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A. Alternative Name :
von Willebrand factor A domain-containing protein 5A; Breast cancer suppressor candidate 1; BCSC-1; Loss of heterozygosity 11 chromosomal region 2 gene A protein; BCSC1; LOH11CR2A Swiss-Prot :
O00534 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide VWA5A. (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS5627 VWA5A pAb.
Blocking peptide available as BS5627PP